HassellKL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 suppl):S512-S521.
2.
SmithLAOyekuSOHomerCZuckermanB. Sickle cell disease: a question of equity and quality. Pediatrics. 2006;117:1763-1770.
3.
American College of Physicians. Achieving a high-performance health care system with universal access: what the United States can learn from other countries. Ann Intern Med. 2008;148:55-75.
4.
CharacheSTerrinMMooreR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322.
5.
SteinbergMHBartonFCastroO. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-1651.
6.
LanzkronSHaywoodCFaganPJRandCS. Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved. 2010;21:277-286.
7.
PrabhakarHHaywoodCMolokieR. Sickle cell disease in the United States: looking back and forward at 100 years of progress in management and survival. Am J Hematol. 2010;85:346-353.
8.
BrawleyOWCorneliusLJEdwardsLR. National Institutes of Health Consensus Development conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148:932-938.
QaseemASnowVOwensDKShekelleP.Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med. 2010;153:194-199.
15.
McCabeCKirchnerCZhangHDaleyJFismanDN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med. 2009;169:1525-1531.
